Dexamethasone Sodium Phosphate

• Intravenous or intramuscular administration.
  When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows:
  • Endocrine disorders.
    Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).

    Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used).

    Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.

    Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.

    Congenital adrenal hyperplasia.

    Nonsuppurative thyroiditis.

    Hypercalcemia associated with cancer.

  • Rheumatic disorders.
    As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

    Post-traumatic osteoarthritis.

    Synovitis of osteoarthritis.

    Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).

    Acute and subacute bursitis.

    Epicondylitis.

    Acute nonspecific tenosynovitis.

    Acute gouty arthritis.

    Psoriatic arthritis.

    Ankylosing spondylitis.

  • Collagen diseases.
    During an exacerbation or as maintenance therapy in selected cases of:

    Systemic lupus erythematosus.

    Acute rheumatic carditis.

  • Dermatologic diseases.

    Pemphigus.

    Severe erythema multiforme (Stevens-Johnson Syndrome).

    Exfoliative dermatitis.

    Bullous dermatitis herpetiformis.

    Severe seborrheic dermatitis.

    Severe psoriasis.

    Mycosis fungoides.

  • Allergic states.
    Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in:

    Bronchial asthma.

    Contact dermatitis.

    Atopic dermatitis.

    Serum sickness.

    Seasonal or perennial allergic rhinitis.

    Drug hypersensitivity reactions.

    Urticarial transfusion reactions.

    Acute noninfectious laryngeal edema (epinephrine is the drug of first choice).

  • Ophthalmic diseases.

    Severe acute and chronic allergic and inflammatory processes involving the eye, such as:

    Herpes zoster ophthalmicus.

    Iritis, iridocyclitis.

    Chorioretinitis.

    Diffuse posterior uveitis and choroiditis.

    Optic neuritis.

    Sympathetic ophthalmia.

    Anterior segment inflammation.

    Allergic conjunctivitis.

    Allergic corneal marginal ulcers.

    Keratitis.

  • Gastrointestinal diseases.
    To tide the patient over a critical period of the disease in:

    Ulcerative colitis (systemic therapy).

    Regional enteritis (systemic therapy).

  • Respiratory diseases.

    Symptomatic Sarcoidosis.

    Berylliosis.

    Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy.

    Loeffler's syndrome not manageable by other means.

    Aspiration pneumonitis.

  • Hematologic disorders.

    Acquired (autoimmune) hemolytic anemia.

    Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated).

    Secondary thrombocytopenia in adults.

    Erythroblastopenia (RBC anemia).

    Congenital (erythroid) hypoplastic anemia.

  • Neoplastic diseases.
    For palliative management of:

    Leukemias and lymphomas in adults.

    Acute leukemia of childhood.

  • Edematous states.
    To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.
  • Nervous system.

    Acute exacerbations of multiple sclerosis.

  • Miscellaneous.

    Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy.

    Trichinosis with neurologic or myocardial involvement.

    Diagnostic testing of adrenocortical hyperfunction.

    Cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management.

• Intra-articular or soft tissue administration.
  When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intra-articular or soft tissue administration are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:

  Synovitis osteoarthritis.

  Rheumatoid arthritis.

  Acute and subacute bursitis.

  Acute gouty arthritis.

  Epicondylitis.

  Acute nonspecific tenosynovitis.

  Post-traumatic osteoarthritis.

• Intralesional administration.
  When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intralesional administration are indicated for:

  Keloids.

  Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis).

  Discoid lupus erythematosus.

  Necrobiosis lipoidica diabeticorum.

  Alopecia areata.

  They also may be useful in cystic tumors of an aponeurosis tendon (ganglia).

• Intravenous or intramuscular administration.

  The initial dosage of Dexamethasone sodium phosphate Injection may vary from 0.50 mg/day to 9.0 mg/day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. Usually the parenteral dosage ranges are one-third to one-half the oral dose given every 12 hours. However, in certain overwhelming, acute, life-threatening situations, administration of dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages.

  For the treatment of unresponsive shock high pharmacologic doses of this product are currently recommended. Reported regimens range from 1 to 6 mg/kg of body weight as a single intravenous injection to 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists.

  For the treatment of cerebral edema in adults an initial intravenous dose of 10 mg is recommended followed by 4 mg intramuscularly every six hours until maximum response has been noted. This regimen may be continued for several days postoperatively in patients requiring brain surgery. Oral dexamethasone, 1 to 3 mg t.i.d., should be given as soon as possible and dosage tapered off over a period of five to seven days. Nonoperative cases may require continuous therapy to remain free of symptoms of increased intracranial pressure. The smallest effective dose should be used in children, preferably orally. This may approximate 0.2 mg/kg/24 hours in divided doses.

  In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day or 4–8 mg dexamethasone every other day for 1 month have been shown to be effective.

  The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, dexamethasone sodium phosphate injection, USP should be discontinued and the patient transferred to other appropriate therapy. It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient.

  After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this later situation it may be necessary to increase the dosage of dexamethasone sodium phosphate injection, USP for a period of time consistent with the patient's condition. If after a long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly.

• Intra-articular, soft tissue or intralesional administration.

  The dose for intrasynovial administration is usually 2 to 4 mg for large joints and 0.8 to 1 mg for small joints. For soft tissue and bursal injections a dose of 2 to 4 mg is recommended. Ganglia require a dose of 1 to 2 mg. A dose of 0.4 to 1 mg is used for injection into tendon sheaths. Injection into intervertebral joints should not be attempted at any time and hip joint injection cannot be recommended as an office procedure.

  Intrasynovial and soft tissue injections should be employed only when affected areas are limited to 1 or 2 sites. It should be remembered that corticoids provide palliation only and that other conventional or curative methods of therapy should be employed when indicated.

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  Frequency of injection usually ranges from once every 3 to 5 days to once every 2 to 3 weeks. Frequent intra-articular injection may cause damage to joint tissue.

Sodium retention

Fluid retention

Congestive heart failure in susceptible patients

Potassium loss

Hypokalemic alkalosis

Hypertension

Muscle weakness

Steroid myopathy

Loss of muscle mass

Osteoporosis

Vertebral compression fractures

Aseptic necrosis of femoral and humeral heads

Pathologic fracture of long bones

Peptic ulcer with possible subsequent perforation and hemorrhage

Pancreatitis

Abdominal distention

Ulcerative esophagitis

Impaired wound healing

Thin fragile skin

Facial erythema

Increased sweating

May suppress reactions to skin tests

Petechiae and ecchymoses

Convulsions

Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment

Vertigo

Headache

Posterior subcapsular cataracts

Increased intraocular pressure

Glaucoma

Menstrual irregularities

Development of cushingoid state

Suppression of growth in children

Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness

Decreased carbohydrate tolerance

Manifestations of latent diabetes mellitus

Increased requirements for insulin or oral hypoglycemic agents in diabetics

Negative nitrogen balance due to protein catabolism

Hyperpigmentation or hypopigmentation

Subcutaneous and cutaneous atrophy

Sterile abscess

Postinjection flare, following intra-articular use

Charcot-like arthropathy

Itching, burning, tingling in the ano-genital region

Dexamethasone Sodium Phosphate Injection, USP is a water-soluble inorganic ester of dexamethasone which produces a rapid response even when injected intramuscularly.

Dexamethasone Sodium Phosphate, C₂₂H₂₈FNa₂O₈P, has a molecular weight of 516.41 and chemically is Pregn-4-ene-3, 20-dione, 9-fluoro-11, 17-dihydroxy-16-methyl-21 (phosphonooxy)-, disodium salt, (11β, 16α).

It occurs as a white to creamy white powder, is exceedingly hygroscopic, is soluble in water and its solutions have a pH between 7.0 and 8.5.

It has the following structural formula:

Dexamethasone Sodium Phosphate Injection, USP is available in 4 mg/mL.

Each mL of Dexamethasone Sodium Phosphate injection contains Dexamethasone Sodium Phosphate, USP equivalent to 4 mg of Dexamethasone Phosphate. Made isotonic with sodium citrate. pH adjusted with citric acid or sodium hydroxide.

Dexamethasone Sodium Phosphate Injection, USP 4 mg/mL is available as:

4 mg/mL in a 1 mL pre-filled disposable single-use syringe (NDC 76045-210-00). Available in a carton of twenty-four (24) syringes. NDC 76045-210-10. This product contains an RFID.

4 mg/mL in a 1 mL pre-filled disposable single-use syringe, NDC 76045-106-10

Available in a carton of twenty-four (24) syringes.

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature.]

Protect from light. Sensitive to heat – Do not autoclave.